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PToward a new cold and warm nondepolarizing, normokalemic arrest
paradigm for orthotopic heart transplantation
Donna M. Rudd, MSc, and Geoffrey P. Dobson, PhD
Objective: Currently, the safe human heart preservation time is limited to around 4 to 5 hours of cold ischemic
storage. Longer arrest times can lead to donor heart damage, early graft dysfunction, and chronic rejection. The
aim of this study was to examine a new nondepolarizing, normokalemic preservation solution with adenosine and
lidocaine for as long as 6 hours of arrest at cold and warmer storage temperatures.
Methods: Isolated perfused rat hearts (n¼ 87) were switched from working to Langendorff (nonworking) mode
and arrested at 37C with 200-mmol/L adenosine and 500-mmol/L lidocaine in Krebs–Henseleit buffer (10-mmol/
L glucose, pH 7.7, 37C) or with Celsior (Sangstat Medical Corp, Fremont, CA). Hearts were removed and placed
in static storage at 4C for 2 and 6 hours or remained on the apparatus and were intermittently flushed at 37C
every 20 minutes for 2 minutes at 68 mm Hg (average arrest temperature 28–30C) for 2 and 6 hours. We further
investigated the effect of the warmer adenosine–lidocaine solution supplemented with 1- or 5-mmol/L pyruvate.
Results: Adenosine–lidocaine solution arrested hearts in 16 2 seconds (n¼ 32), whereas Celsior did so in 39
4 seconds (n ¼ 23). After 2 hours of cold static storage, there were no functional differences between the aden-
osine–lidocaine and Celsior groups, with approximately 70% return of cardiac output. In contrast, after 6 hours of
4C storage, adenosine–lidocaine hearts had significantly higher functional recoveries (68%  5% cardiac out-
put) than Celsior hearts (47% 14% cardiac output) during 60 minutes of reperfusion. In addition, Celsior hearts
took 5 minutes longer to reanimate and showed early reperfusion arrhythmias. At warmer temperatures after 2
hours of arrest, adenosine–lidocaine and Celsior hearts were not significantly different, despite a 43% higher car-
diac output in adenosine–lidocaine hearts (80%  3% vs 56%  12%). After 6 hours, adenosine–lidocaine
hearts had recovered 55%  3% of prearrest cardiac output, which increased significantly to 75%  4%
with addition of 1-mmol/L pyruvate. Adenosine–lidocaine with 1-mmol/L pyruvate hearts spontaneously recov-
ered 106% heart rate, 93% to 105% developed pressures, 70% aortic flow, and 81% coronary flow. Coronary
vascular resistance increased 1.7- to 1.9-fold during the 6-hour arrest. In contrast, Celsior hearts did not have
return of aortic or coronary flow after 6 hours in these warmer conditions.
Conclusion: A new nondepolarizing, normokalemic adenosine–lidocaine arrest solution in Krebs–Henseleit
buffer with 10-mmol/L glucose was versatile at both 4C and 28C to 30C relative to Celsior, and the addition
of 1-mmol/L pyruvate significantly improved cardiac output at warmer arrest temperatures. This new arrest
paradigm may be useful in the harvest, storage, and implantation of donor hearts.Currently, adult donor heart preservation times from harvest
to reanimation are limited to about 4 to 5 hours of cold (2C–
4C) ischemic storage.1-3 Longer arrest times lead to donor
heart damage, early graft dysfunction, and possibly chronic
rejection.4,5 In addition, older hearts are less ischemia toler-
ant than are younger hearts.6 A significant factor leading to
donor heart dysfunction and failure is ineffectiveness of cur-
rent strategies of cardioprotection. A concern during the past
decade has been high concentrations of arresting potassium
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transition during reperfusion and implantation.7,8 Strongly
hyperkalemic solutions, such as University Wisconsin solu-
tion (125-mmol/L potassium ion), arrest the heart by depola-
rizing the membrane from 85 mV to below 50 mV,
whereas mildly hyperkalemic solutions, such as Celsior so-
lution (15-mmol/L potassium ion) (Sangstat Medical Corp,
Fremont, CA) and St Thomas’ Hospital solution No. 2, de-
polarize the membrane to around50 mV.9 Depolarizing po-
tassium has no intrinsic cardioprotective properties beyond
inducing cardioplegic arrest. High potassium can lead to cor-
onary vasoconstriction and compromise cardioplegia deliv-
ery and distribution,10,11 damage the vascular endothelium
and myocytes,12 promote myocardial electrical instability
and arrhythmias,13 and lead to myocardial stunning.14 A
large part of potassium’s untoward effects on the heart is
thought to arise from intracellular sodium and calcium ion
loading and oxidative stress, which can lead to mitochon-
drial impairment, necrosis, and apoptosis.15 High-potassium
solutions may also lead to microcirculatory disturbances,gery c January 2009
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such as erythrocyte deformability, observed frequently after
restoration of the circulation in transplanted organs.16
For more than 10 years, our laboratory has focused on de-
veloping a normokalemic nondepolarizing cardioplegia that
clamps the membrane potential closer to its resting voltage
of 83 mV by using an adenosine–lidocaine combination
(AL) as the active arrest composition.17 Our innovation bor-
rows from natural hibernators and places the heart in a more
‘‘natural’’ state of suspended animation.18 We have shown
that the AL cardioplegia can arrest the heart for as long as
4 hours with 70% to 80% recovery of the cardiac output;
85% to 100% recovery of heart rate, systolic pressure,
and rate–pressure product, and 70% to 80% of baseline cor-
onary flows. Only 14% of hearts arrested with St Thomas’
Hospital solution No. 2 survived after 4 hours.17 We have
also recently demonstrated proof of concept in the canine
model of cardiopulmonary bypass.19
Our aims in this study were to compare cold AL cardio-
plegia with AL at warmer temperatures, to compare AL
with Celsior preservation solution in both states, and to
test the effect of adding 1- and 5-mmol/L L-pyruvate to the
AL solution at the warmer arrest temperatures. We found
that AL solution is versatile at both 4C and 28C to 30C
and that the addition of 1-mmol/L pyruvate significantly im-
proves cardiac output at warmer arrest temperatures. Celsior
solution showed equivalence at 2 hours of arrest but failed to
return aortic flow after 6 hours of arrest at 28C to 30C. Our
new AL arrest paradigm may find utility in the harvest, ex
vivo storage, and implantation of donor hearts at hypother-
mic to warmer temperatures.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (350–450 g, n ¼ 87) were obtained from
James Cook University’s breeding colony. Animals were fed ad libitum
and housed in a 12-hour light/dark cycle. On the day of experiment, rats
were anesthetized with an intraperitoneal injection of sodium pentobarbital
(Nembutal, 60 mg/kg body weight), and the hearts were rapidly excised as
described in the report of Dobson and Jones.17 Rats were handled in com-
pliance with James Cook University Guidelines (ethics approval number
A781) and with the Guide for the Care and Use of Laboratory Animals
(www.nap.edu/catalog/5140.html). Adenosine (A9251,>99% purity), so-
dium L-pyruvate, and all other chemicals were obtained from Sigma Chem-
ical Co (Castle Hill, NSW, Australia). Lidocaine hydrochloride was
purchased as a 2% solution (ilium) from the local Pharmaceutical Supplies
(Lyppard, Queensland, Australia).
Compositions of Buffers and Arrest Solutions
Krebs–Henseleit perfusion buffer. Hearts were perfused in the
Langendorff and working modes with a modified Krebs–Henseleit bufferThe Journal of Thoracic and Ccontaining 10-mmol/L glucose, 117 mmol/L sodium chloride, 5.9-mmol/L
potassium chloride, 25-mmol/L sodium hydrogen carbonate, 1.2-mmol/L
sodium dihydrogenphosphate, 1.12-mmol/L calcium chloride (1.07-mmol/
L free calcium ion), and 0.512-mmol/L magnesium chloride (0.5-mmol/L
free magnesium ion), pH 7.4, at 37C. The perfusion buffer was filtered
with a 1-mm membrane and then bubbled vigorously with 95% oxygen
and 5% carbon dioxide to achieve a PO2 greater than 600 mm Hg. The per-
fusion buffer was not recirculated.
Arrest solutions. The AL solution was made fresh daily and con-
tained 200-mmmol/L adenosine plus 500-mmol/L lidocaine in 10-mmol/L
glucose-containing Krebs–Henseleit buffer (pH 7.7 at 37C), as described
by Dobson and Jones.17 The AL arrest solution was filtered with 0.2-mm fil-
ters and maintained at 37C. The arrest solution was not actively bubbled
with 95% oxygen and 5% carbon dioxide, leading to a higher pH. The av-
erage PO2 of the AL solution was 131 mm Hg, and the PCO2 was 5 to 10 mm
Hg. The Celsior solution was made fresh daily and contained 100-mmol/L
sodium hydroxide, 15-mmol/L potassium chloride, 13-mmol/L magnesium
chloride, 0.25-mmol/L calcium chloride, 20-mmol/L glutamic acid, 80-
mmol/L lactobionic acid, 30-mmol/L histidine, and 3-mmmol/L glutathione
(pH 7.3). The solution was filtered with a 0.2-mm filter, was not actively
bubbled with 95% and 5% carbon dioxide, and had an average PO2 of
127.4 mm Hg.
Experimental Groups
Rats were randomly assigned to 1 of 6 arrest and storage protocols for
either 2 or 6 hours: (1) AL alone for cold (4C) static storage (n ¼ 16),
(2) AL alone with warmer (28C–30C) intermittent infusions (n ¼ 16),
(3) AL plus 1-mmol/L pyruvate with warmer (28C–30C) intermittent
infusions (n ¼ 16), (4) AL plus 5-mmol/L pyruvate with warmer
28C–30C intermittent infusions (n¼ 16), (5) Celsior for cold (4C) static
storage (n¼ 11), and (6) Celsior with warmer (28C–30C) intermittent in-
fusions (n¼ 12). Although Celsior is an extracellular-type solution not orig-
inally designed for warmer temperatures, the last protocol was included for
comparison with AL cardioplegia, because Celsior was designed in part to
reduce injury to the heart in the transition from cold to warm reperfusion.20
Langendorff and Working Rat Heart Preparations
Hearts were rapidly removed from anesthetized rats and immediately
placed in ice-cold Krebs–Henseleit buffer. Briefly, excess tissue was re-
moved, and the heart was connected by the aorta to a standard Langendorff
apparatus and perfused in a retrograde fashion with a perfusion pressure of
90 cm H2O (68 mm Hg). After the pulmonary veins and superior and infe-
rior venae cavae were tied off to minimize leaks (<1 mL/min), the pulmo-
nary artery was cannulated for collection of coronary venous effluent. A
small incision was made in the left atrial appendage, into which another can-
nula was inserted and tied off for working mode operation. The preparation
was then switched to the working mode by switching the supply of perfusate
from the aorta to the left atrial cannula at a hydrostatic pressure of 10 cm
H2O (preload) and an afterload of 100 cm H2O (76 mm Hg). The heart
was deliberately not placed in a thermostat-equipped jacket, so that moder-
ate decreases in temperature during arrest would mimic the clinical drift in
myocardial temperature. Hearts were stabilized for 15 minutes before con-
version back to Langendorff nonworking mode before induction of arrest.
Heart rate, aortic pressure, coronary flow, and aortic flow were measured be-
fore, during, and after arrest.
Aortic pressure was measured continuously with a pressure transducer
(ADI Instruments, Sydney, NSW, Australia) coupled to a MacLab 2e
(ADI Instruments). Systolic and diastolic pressures and heart rate were cal-
culated from the pressure trace with the MacLab software. Arterial and ve-
nous perfusate PO2 and PCO2, pH, and ionic (calcium, chloride, and sodium)
concentrations were measured with a Bayer 865 blood gas machine (Sie-
mens Australia, Bayswater, Victoria, Australia). Coronary flow and aortic
flow were measured in volumetric cylinders. The initial criteria for exclu-
sion of working hearts during the 15-minute equilibration period wereardiovascular Surgery c Volume 137, Number 1 199
Cardiopulmonary Support and Physiology Rudd and Dobson
C
S
Pa heart rate less than 200 beats/min, a systolic pressure less than 100 mm Hg,
and a coronary flow less than 10 mL/min. Neither pacing nor cardiac
massage was used during the reanimation phase in the working mode.
The surface temperature of the heart was measured with a Cole-Parmer
thermistor-thermometer (8402-20; Cole-Parmer, Vernon Hills, Ill) with
the thermistor probe tucked under the left auricle. We previously have
shown that placement in the left heart chamber yields similar profiles to sub-
auricular placement.17 The perfusion apparatus was flushed weekly with 5 L
of 3% hydrogen peroxide and 1% glacial acetic acid solution, followed by
a thorough rinse with 10 L 18-MU water.
Cold Static Storage (4C)
We used the cold static storage method of McDonald and colleagues21
with the following modifications. Baseline data were obtained for hearts
in working mode at 37C. Arrest was induced in the Langendorff mode at
normothermia with a 5-minute infusion of cardioplegia solution (50–100
mL) through the aorta at a constant pressure of 68 mm Hg. Hearts were
then gently removed from the working heart apparatus, placed in 50-mL
tubes containing their respective preservation solutions, and immersed in
the water bath set at 4C for 2 or 6 hours. After storage, the hearts were re-
turned to the perfusion apparatus, and fresh arrest solutions were perfused in
Langendorff mode. The hearts were slowly rewarmed for 5 minutes before
reanimation and reperfusion in working mode for 60 minutes at 37C with
oxygenated, glucose-containing Krebs–Henseleit solution at pH 7.4. Func-
tional data (aortic and coronary flows, heart rate, and systolic and diastolic
pressures) were measured at predetermined times before arrest and during
60 minutes of reperfusion and compared with the baseline data for each
heart.
Intermittent Cardioplegic Delivery at Warmer
Arrest Temperatures (28C–30C)
The method of intermittent cardioplegic delivery in the isolated rat heart
has been previously described by Dobson and Jones.17 Arrest in the Langen-
dorff mode was induced by a 5-minute infusion of cardioplegic solution
(50–100 mL) through the aorta at 37C and a constant pressure of 68 mm
Hg. After arrest, the aorta was crossclamped at the completion of infusion
with a plastic atraumatic aortic clip. Cardioplegia was replenished every
18 minutes with a 2-min infusion, after which the crossclamp was reapplied.
After 2 or 6 hours of arrest with intermittent cardioplegic delivery, the heart
was switched immediately to the working mode and reperfused with oxy-
genated, glucose-containing Krebs–Henseleit buffer at 37C. The heart tem-
perature during intermittent arrest ranged from 35C during delivery to
about 25C before the next delivery (average 28–30C), as directly mea-
sured and discussed by Dobson and Jones.17 The working heart was chosen
because the ejecting model is more representative of the natural flow
through the heart, whereas the standard Langendorff model receives rever-
sal of flow through the aorta and does no physical work.
Determination of Coronary Vascular Resistance
During Warmer Intermittent Delivery and of Total
Tissue Water
Coronary vascular resistance (CVR, Mdyne $ s $ cm5) was calculated
during each 2-minute cardioplegic delivery by dividing delivery pressure
by flow (volume per second) according to the following equation: CVR
¼ 1333 3 pressure (in mm Hg) 3 106/flow (in mL/s), where 1 mm Hg
is equal to 1333 dyne/cm2 and 106 is a conversion factor from dynes to
megadynes.
Total tissue water (as a percentage) was determined by the difference in
wet weight and dry weight divided by wet weight and multiplied by 100%.
Powdered tissues were obtained from hearts receiving AL, AL with
1-mmol/L pyruvate, and AL with 5-mmol/L pyruvate. After 60 minutes
of reperfusion, hearts were dried to a constant weight at 85C for as long
as 48 hours.200 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
All results are expressed as mean SEM. Statistics were performed sep-
arately for the 2-hour and 6-hour protocols. One-way analysis of variance
was used to compare rats in weight, arrest times, time to first beat, heart
rate, developed pressure, rate–pressure product, aortic flow, coronary
flow, and cardiac output at separate time points (Table 1 and 2). Two-
way analysis of variance with repeated measures was used to compare func-
tional variables during 60 minutes of recovery across multiple time points
for the different treatment groups (Figure 1). Significance was then assessed
with Bonferroni and Dunnet (2-sided) post hoc tests. The alpha level of sig-
nificance for all experiments was set at P<0.05.
RESULTS
Arrest Times
Full normothermic electrochemical arrest in hearts with
AL and no added pyruvate was achieved in 16  2 seconds
(n ¼ 32), not significantly different from AL with the
presence of 1-mmol pyruvate (25  8 seconds, n ¼ 16) or
5-mmol/L pyruvate (18  4 seconds, n ¼ 16). Hearts with
Celsior took a longer time to arrest (39 4 seconds, n¼ 23);
however, this arrest time was not significantly different from
the arrest times in the AL groups.
Cold Static Storage (4C): Functional Recoveries
After 2 and 6 Hours of Arrest
The functional data for the AL and Celsior groups under-
going cold immersion storage for 2 and 6 hours are shown in
Tables 1 and 2, respectively. After 2 hours, there were no
functional differences between the AL and Celsior groups.
At 60 minutes of reperfusion in working mode, heart rates
were 94% to 103% of prearrest values, systolic pressures
92% to 93%, diastolic pressures 99% to 106%, rate–pres-
sure products 92% to 98%, aortic flows 65% to 70%, cor-
onary flows 82% to 86%, and cardiac outputs 69% to 72%
(Table 1).
After 6 hours of cold static storage (4C), the hearts in the
AL group had spontaneously returned to 105% of prearrest
heart rate, 90% of prearrest systolic pressure, 105% of pre-
arrest diastolic pressure, 94% of prearrest rate–pressure
product, 66% of prearrest aortic flow, 84% of prearrest cor-
onary flow, and 69% of prearrest cardiac output (Table 2). In
contrast, hearts in the Celsior group had returned to signifi-
cantly lower functional parameters after 60 minutes of reper-
fusion according to a 2-way analysis of variance with
repeated measures (P ¼ .006). Hearts in the Celsior group
had returned to 81% of prearrest heart rate, 69% of prearrest
systolic pressure, 93% of prearrest diastolic pressure, 63%
of prearrest rate–pressure product, 41% of prearrest aortic
flow, 47% of prearrest coronary flow, and 49% of prearrest
cardiac output at 60 minutes reperfusion after 6 hours of
static storage arrest (Table 2). Despite the same protocol of
reattachment and rewarming of hearts (5 minutes) after
cold static storage, hearts in the Celsior group took 5 minutes
longer to reanimate in working mode than did those in the
AL group (Figure 1, A) and showed early reperfusiongery c January 2009
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Treatment n
Heart rate
(beats/min)
Pressure (mm Hg) Rate–pressure
product (mm Hg/min)
Aortic
flow (mL/min)
Coronary
flow (mL/min)
Cardiac
output (mL/min)
Systolic Diastolic Value %PA Value %PA Value %PA
15 min before arrest
AL cold (4C) 8 288  4 121  2 60  1 34,696  664 62  1 21  1 83  2
Celsior (4C) 6 285  9 121  1 60  0 34,406  1153 60  4 20  2 80  5
AL (29C) 8 268  8 121  2 60  0 32,299  920 48  2 16  1 64  2
Plus 1-mmol/L Pyr 8 270  8 121  1 59  1 32,688  738 46  2 16  1 62  3
Plus 5-mmol/L Pyr 8 274  9 119  1 56  2 32,499  1098 51  3 18  1 70  4
Celsior (29C) 6 281  6 123  2 60  0 34,397  682 56  1 17  1 73  2
15 min recovery
AL cold (4C) 8 284  11 113  4 59  1 31,944  979 42  5 68  5 15  1 71 56  6 67
Celsior (4C) 6 263  21 108  3 63  2 28,085  1991 34  5 57  9 13  1 65 47  5 59
AL (29C) 8 238  8 113  4 60  0 26,833  1312 32  3 67  4 15  1 94 47  3 73
Plus 1-mmol/L Pyr 8 240  10 116  2 65  3 27,874  959 31  4 67  6 16  1 100 46  3 74
Plus 5-mmol/L Pyr 8 230  14 115  3 59  1 26,223  1124 28  3 55  4 17  1 94 44  5 63
Celsior (29C) 6 203  45 95  20 52  11 23,320  5424 23  8 41  15 14  3 82 38  10 52
30 min recovery
AL cold (4C) 8 293  14 115  4 59  1 33,359  694 46  3 74  3 15  1 71 61  2 73
Celsior (4C) 6 269  14 113  3 64  2 30,228  1595 40  3 67  7 14  1 70 54  3 68
AL (29C) 8 268  12 111  4 60  0 29,633  1173 37  2 77  3 16  1 100 52  3 81
Plus 1-mmol/L Pyr 8 265  9 113  3 64  2 29,679  735 37  2 80  3 16  1 100 54  2 87
Plus 5-mmol/L Pyr 8 249  7 116  2 59  1 28,924  616 41  3 80  2 16  1 89 58  4 83
Celsior (29C) 6 226  46 89  19 52  10 24,152  5038 26  7 46  12 13  3 76 40  8 55
60 min recovery
AL cold (4C) 8 303  14 113  3 59  1 33,991  751 42  3 68  3 18  1 86 60  2 72
Celsior (4C) 6 267  10 111  3 64  2 31,773  1010 38  1 63  3 16  1 80 54  1 68
AL (29C) 8 285  15 110  4 60  0 31,233  1451 36  3 75  3 15  1 94 51  3 80
Plus 1-mmol/L Pyr 8 287  14 113  3 65  3 32,336  1629 38  2 83  3 16  1 100 53  2 86
Plus 5-mmol/L Pyr 8 256  9 114  3 59  1 28,963  431 39  3 76  3 15  1 83 55  4 79
Celsior (29C) 6 230  47 91  19 51  10 25,043  5167 26  7 46  12 14  3 82 41  9 56
Functional parameters of isolated working rat hearts before arrest and during 60 minutes of reperfusion after 2-hour arrest with adenosine–lidocaine cardioplegia or Celsior (Sang-
stat Medical Corp, Fremont, CA) during cold static storage (4C) and after cardioplegia with adenosine–lidocaine with L-pyruvate at 0, 1, or 5 mmol/L or with Celsior intermittently
perfused every 20 minutes for 2 minutes at 68 mm Hg and 37C (average arrest temperature 28C–30C; see Material and Methods section for details).%PA, Percentage of pre-
arrest value; AL, adenosine–lidocaine; Pyr, L-pyruvate.C
S
Parrhythmias relative to those in the AL group as well (data
not shown). Hearts in the AL group had returned to a signif-
icantly higher cardiac output (45% higher) than had those in
the Celsior group after 60 minutes of reperfusion after 6
hours of arrest (Figure 1, A).
Warmer Arrest With Intermittent Flushes (28C–
30C): Cardioplegic Volumes, CVRs, and Recoveries
After 2 and 6 Hours of Arrest
The total cardioplegic volumes for hearts with 0-, 1-, and 5-
mmol/L pyruvate delivered with AL cardioplegia during the
2-hour arrest period were 222 17, 287 11, and 313 15
mL, respectively; those with cardioplegia delivered during 6
hours were 519  33, 509  39, and 652  26 mL. Hearts
receiving AL supplemented with 5-mmol/L pyruvate had
significantly higher total volumes infused than hearts receiv-
ing AL with either 0- or 1-mmol/L pyruvate (P¼ .014). The
total cardioplegic volumes for hearts with Celsior delivered
during 2 and 6 hours of arrest were 293  20 mL and 411The Journal of Thoracic and C 53 mL, respectively. Hearts receiving Celsior solution
had 21% to 37% lower total volumes than did the AL groups,
but these differences were not significantly different.
The values of CVR before cardioplegic arrest for hearts
perfused with AL solution with 0-, 1-, and 5-mmol/L pyru-
vate and those perfused with Celsior were 0.32  0.02, 0.35
 0.01, 0.33  0.01, and 0.31  0.02 Mdyne $ s $ cm5, re-
spectively (Figure 2). The prearrest CVRs were not signifi-
cantly different. During 2 minutes of intermittent
infusions, CVRs in the three AL groups increased by 1.3
times at 3 hours to 1.7 and 1.9 times at 6 hours (not signifi-
cant, between AL groups). The CVR in the Celsior group in-
creased 1.8 times (0.56  0.08 Mdyne $ s $ cm5) at 3 hours
and 2.8 times (0.86  0.17) at 6 hours. At 3 hours, the CVR
values for the Celsior group were significantly higher than
for AL with 5-mmol/L pyruvate (0.56 vs 0.36 Mdyne $ s $
cm5) and AL solution alone (0.56 vs 0.42 Mdyne $ s $
cm5; P ¼ .027). Despite the Celsior group having 30% to
76% higher CVR at 6 hours than the AL groups, however,ardiovascular Surgery c Volume 137, Number 1 201
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Treatment n
Heart rate
(beats/min)
Pressure (mm Hg) Rate–pressure
product (mm Hg/min)
Aortic
flow (mL/min)
Coronary
flow (mL/min)
Cardiac
output (mL/min)
Systolic Diastolic Value %PA Value %PA Value %PA
15 min before arrest
AL cold (4C) 8 279  9 123  3 60  0 34,296  895 61  2 20  2 81  3
Celsior (4C) 5 295  19 121  4 60  0 35,529  1744 54  4 22  2 76  5
AL (29C) 8 297  10 124  3 60  0 36,989  1386 48  2 17  1 65  3
Plus 1-mmol/L Pyr 8 271  7 122  2 60  0 33,253  1245 50  3 16  1 65  4
Plus 5-mmol/L Pyr 8 264  10 120  0 56  2 31,695  1151 49  2 17  1 65  2
Celsior (29C) 6 259  5 127  2 60  0 32,920  306 54  1 18  1 72  1
15 min recovery
AL cold (4C) 8 253  14 108  4* 63  2* 27,144  1653* 30  4* 49 15  1 75 45  4* 55
Celsior (4C) 6 189  46 75  24 44  12 16,649  6141 17  7 32 10  3 46 27  10 36
AL (29C) 8 230  16 111  2* 61  1* 25,548  1793 19  3 40 12  1 71 31  4 48
Plus 1-mmol/L Pyr 8 256  10* 114  2* 65  3* 29,110  990* 26  2 52 14  1 88 41  3 63
Plus 5-mmol/L Pyr 8 238  7 101  1* 60  0* 24,084  678 15  2 31 14  1 82 29  2 45
Celsior (29C) 6 0  0y 6  3y 4  3y 0  0y 0  0y 0y 1  1y 1y 1  1y 0y
30 min recovery
AL cold (4C) 6 289  13 109  3 61  1* 31,476  932 39  3* 61 16  2* 80* 53  3* 65
Celsior (4C) 6 237  47 88  19 56  12 24,303  6080 22  7 41 12  2 55 34  9 45
AL (29C) 8 259  12 111  3 61  4* 28,615  1131 21  2 44 12  1 71 33  3 51
Plus 1-mmol/L Pyr 8 269  13 113  3* 63  2* 30,224  1043 32  3 64 13  1 81 47  4 72
Plus 5-mmol/L Pyr 8 269  11 103  2 60  0* 27,579  1093 24  3 49 13  1 77 37  3 57
Celsior (29C) 6 0.0  0.0y 4  2y 3  2y 0  0y 0  0y 0y 1  1y 1y 1  1y 0y
60 min recovery
AL cold (4C) 6 292  12 111  3* 63  2* 32,392  837* 37  3* 64 16  2* 80 55  3* 68*
Celsior (4C) 6 240  61 84  19 56  12 22,257  6248 25  7 46 11  2 50 36  10 47
AL (29C) 8 281  11 109  2* 65  2* 30,470  1085 24  2 50 13  1 76 36  3 55
Plus 1-mmol/L Pyr 8 286  14 113  3* 63  2* 32,060  982* 35  3 70 13  1 81 49  4 75
Plus 5-mmol/L Pyr 8 280  11 101  1* 60  0* 28,353  1299 24  3 49 13  1 76 37  4 57
Celsior (29C) 6 0  0y 4  2y 1  1y 0  0y 0  0y 0y 1  1y 1y 1  1y 0
Functional parameters of isolated working rat hearts before arrest and during 60 minutes of reperfusion after 6-hour arrest with adenosine–lidocaine cardioplegia or Celsior (Sang-
stat Medical Corp, Fremont, CA) during cold static storage (4C) and after cardioplegia with adenosine–lidocaine with L-pyruvate at 0, 1, or 5 mmol/L or with Celsior intermittently
perfused every 20 minutes for 2 minutes at 68 mm Hg and 37C (average arrest temperature 28C–30C; see Material and Methods section for details).%PA, Percentage of pre-
arrest value; AL, adenosine–lidocaine; Pyr, L-pyruvate. *Significant at P< .05 between adenosine–lidocaine treatment groups and Celsior group according to 1-way analysis of
variance at each time point. ySignificant at P<.001 between adenosine–lidocaine treatment groups and Celsior group according to 1-way analysis of variance at each time point.the differences failed to reach statistical significance, in part
because of the large SEs of the Celsior group (Figure 2).
Recovery of functional parameters in hearts arrested at
warmer temperatures (heart arrest temperatures 28C–
30C) for 2 and 6 hours are shown in Tables 1 and 2. After
2 hours of arrest with AL cardioplegia, recovery of prearrest
heart rate was 106% 5%, that of prearrest aortic flow was
75% 3%, and that of prearrest coronary flow was 94%
5% (Table 1). The addition of 1-mmol/L pyruvate increased
recovery of prearrest aortic flow from 75% 3% to 83%
3%; however, this was not significant. Similarly, the addi-
tion of 1-mmol pyruvate led to no significant changes
in heart rate (106% 4%) or coronary flow (100% 3%)
recovery relative to AL alone (Table 1). The addition of
5-mmol pyruvate to AL led to decreases in heart rate, aortic
flow, and coronary flow of around 10% to 14%; however,
these changes were not significantly different from AL sup-
plemented with 0- or 1-mmol/L pyruvate. Rate–pressure202 The Journal of Thoracic and Cardiovascular Suproducts for AL with 0-, 1-, and 5-mmol/L pyruvate were
90% to 99% of prearrest values and not significantly differ-
ent from each other. Cardiac outputs with AL supplemented
with 0-, 1-, and 5-mmol/L pyruvate were 80%  3%, 86%
 2%, and 79%  3% of prearrest values at 60 minutes of
reperfusion after 2 hours of arrest and not significantly dif-
ferent from each other. After 2 hours of arrest with Celsior
cardioplegia, recovery of prearrest heart rate was 82%,
that of prearrest aortic flow was 26% 7%, and that of pre-
arrest coronary flow was 82%  18% (Table 1). Systolic
and diastolic pressures were 74% and 85% of prearrest
values, rate–pressure product was 73% of prearrest value,
and cardiac output was 56% of prearrest value (Table 1).
Even though all three groups of AL hearts had a 65% to
80% higher aortic flow and 40% to 65% higher cardiac out-
put than the Celsior group, the differences were not signifi-
cant, in part because of the higher SEs in the Celsior group
after 2 hours of arrest at the warmer temperatures (Table 1).rgery c January 2009
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FIGURE 1. (A) Percentage recoveries of cardiac output during 60 minutes of reperfusion after 6 hours of cold (4C) static storage with adenosine–lidocaine
(AL) cardioplegia alone (squares) and with Celsior (crosses). Cardiac output is expressed as percentage of value 5 minutes before arrest. Values are mean 
SEM. Asterisk indicates significant difference between adenosine–lidocaine and Celsior (P<.05) by 2-way analysis of variance with repeated measures (see
Materials and Methods section). (B) Percentage recoveries of cardiac output during 60 minutes of reperfusion after 6 hours of arrest at 28C to 30C with
adenosine–lidocaine cardioplegia supplemented with 0-mmol/L L-pyruvate (Pyr, circles), 1-mmol/L L-pyruvate (squares), or 5-mmol/L L-pyruvate (crosses)
or with Celsior (triangles). All adenosine–lidocaine groups had significantly higher cardiac output than Celsior group (P< .0001). Asterisk indicates aden-
osine–lidocaine with 1-mmol/L pyruvate preserved significantly higher cardiac output than with 0- or 5-mmol pyruvate (P< .05) by 2-way analysis of
variance with repeated measures (see Materials and Methods section).
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S
PAfter 6 hours of intermittent cardioplegia and during 60
minutes of reperfusion, in hearts with AL alone recovery of
prearrest heart rate was 95% 3%, recovery of prearrest aor-
tic flow was 50%  3%, and recovery of prearrest coronary
flow was 76%  4% values (Table 2). The addition of 1-
mmol/L pyruvate to AL cardioplegia significantly increased
recovery of aortic flow during the 60-minute reperfusion pe-
riod (P ¼ .016); however, neither heart rate nor coronary
flow was significantly changed (Table 2). The increase in aor-
tic flow in the presence of 1-mmol/L pyruvate was apparent at
all reperfusion times (15, 30, 45, and 60 minutes; Table 2).The Journal of Thoracic and CCardiac output (aortic flow plus coronary flow) was also
significantly higher in hearts with AL in the presence of
1-mmol/L pyruvate (49 4 mL/min) (P¼ .026) than in those
with AL with 0-mmol/L pyruvate (36  3 mL/min) or with
5-mmol/L pyruvate (37 4 mL/min; Figure 1, B). Rate–pres-
sure products for hearts perfused with AL with 0-, 1-, and
5-mmol/L pyruvate were 82%, 96%, and 90% of prearrest
values and not significantly different from each other. Under
identical 6-hour arrest conditions, hearts perfused with Celsior
did not have return of a heart rate, developed pressures
(4 mm Hg), and aortic and coronary flows and therefore hadardiovascular Surgery c Volume 137, Number 1 203
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FIGURE 2. Coronary vascular resistance during 6 hours of arrest for adenosine–lidocaine (AL) cardioplegia supplemented with 0-mmol/L L-pyruvate (Pyr,
circles), 1-mmol/L L-pyruvate (squares), or 5-mmol/L L-pyruvate (diamonds) or with Celsior (Sangstat Medical Corp, Fremont, CA) (triangles). Coronary
vascular resistance was calculated during 2-minute cardioplegia delivery every 18 minutes during total arrest time. Values are mean SEM. For clarity, only
6-hour arrest data are presented. No significant differences were found between any group at baseline. There were no significant differences in first 2 hours
between the 2- and 6-hour arrest protocols for all adenosine–lidocaine groups. Asterisk indicates at 178 minutes hearts treated with adenosine–lidocaine plus
5-mmol/L pyruvate and with adenosine–lidocaine alone had significantly lower coronary vascular resistance than those treated with Celsior (P< .05).no cardiac output during the 60-minute reperfusion (Figure 1,
B,Table 2). In direct contrast to the AL group, heart in the Cel-
sior group were visibly small, hard, distorted, and discolored.
Values of total tissue water for AL-perfused hearts after 2
and 6 hours of cold static storage and 60 minutes reperfusion
were 84% 1% and 86% 1%, respectively. For hearts in
the Celsior group, the total tissue water values were 82% 
2% and 84% 1% for 2 and 6 hours of cold static storage,
respectively. After warm intermittent arrest and 60 minutes
of reperfusion, the total tissue water values were 87% 
1%, 88%  1%, and 87%  1% for AL with 0-, 1-, and
5-mmol/L pyruvate, respectively (not significantly differ-
ent). The total tissue water for hearts in the Celsior group
was 84%  4% and was not significantly different from
the AL groups.
DISCUSSION
For more than 3 decades, protocols for heart retrieval and
preservation solutions have relied almost exclusively on hy-
perkalemic depolarizing arrest, static storage, and profound
hypothermia.1,3 Of the 167 different types of heart solution
in the United States,22 no single solution has demonstrated
consistent, clinically significant improvement relative to
the others, including protection of the transplanted organ
in the transition from cold to warm during poststorage im-
plantation.2 In our quest to develop a new nondepolarizing,
normokalemic transplant paradigm, we report that AL cardi-
oplegia is versatile at both 4C and at 28C to 30C for as204 The Journal of Thoracic and Cardiovascular Surlong as 6 hours, and the addition of 1-mmol/L pyruvate to
the warmer cardioplegia significantly improves recovery of
cardiac output by 36%. After arrest, AL-treated hearts
with 1-mmol/L pyruvate added had spontaneously returned
to 106% of prearrest heart rate, 93% to 105% of prearrest
developed pressures, 70% of prearrest aortic flow, 81% of
prearrest coronary flow, and 75% of prearrest cardiac output
working against a pressure head of 76 mm Hg (100 cm
H2O). In addition, the CVR in AL-treated hearts increased
less than 2-fold during the 6-hour arrest period at the warmer
arrest temperatures. Whereas hearts infused with AL cardio-
plegia showed functional equivalency with those infused
with Celsior after 2 hours of cold and warm arrest, AL-
infused hearts showed significantly improved outcomes after
6 hours. After 6 hours of intermittent delivery at 28C to
30C, Celsior-infused hearts had no recovery of heart rate,
developed pressures, and cardiac output, whereas the three
AL groups had recovery of 55% to 75% of cardiac output.
Cold Static Storage for 2 and 6 Hours (4C)
Currently, cold static storage is the most widely used form of
preservation in heart transplant practice.3 In this study, we
showed functional equivalence between AL cardioplegia and
Celsior after 2 hours of static storage, with around 70% return
of cardiac output (Table 1). After 6 hours of cold static storage,
however, the AL group had significantly higher functional re-
covery values, with a 22% higher heart rate, 32% higher sys-
tolic pressures, a 46% higher rate–pressure product, a 48%gery c January 2009
Rudd and Dobson Cardiopulmonary Support and Physiology
C
S
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higher cardiac output (Table 2, Figure 1, A). A lower recovery
in Celsior-treated hearts after 6 hours is in good agreement with
the isolated working rat heart study of McDonald and col-
leagues,21 which showed a return of prearrest cardiac output
of 22%  9% (15% aortic flow and 31% coronary flow) at
30 minutes of reperfusion after 6 hours of static storage at
2C to 3C. McDonald and colleagues21 further reported that
the cardiac output increased to about 70% with the addition
of cariporide and glyceryl trinitrate to Celsior. Surprisingly
there are few isolated working heart studies in the literature
comparing Celsior with other preservation solutions, because
most researchers prefer to use Langendorff hearts, which per-
form no physical work (adenosine triphosphate turnover with
zero work, i.e. force times vertical distance). High heart rates
and 90% to 100% returns of prearrest developed pressures
in nonworking Langendorff mode may not necessarily trans-
late to improved pump function. The working rat heart study
of Nickless and associates23 showed approximately 80% re-
covery of prearrest cardiac output (71% aortic flow and
93% coronary flow) after 5 hours of cold (2C) immersion
in University of Wisconsin solution. Unfortunately, these
workers did not report functional recovery data beyond 15 min-
utes of reperfusion, precluding a direct comparison with AL-in-
fused hearts during 60 minutes of reperfusion.
Another important difference between our study and previ-
ous studies using Langendorff or working rat heart prepara-
tions is that we induced arrest at 37C, whereas others
appear to have induced arrest at cold temperatures.21,23 To
summarize, although functional recovery of AL-arrested hearts
was superior to that of Celsior-arrested hearts after 6 hours of
cold static storage, further studies are required to optimize
the AL solution at these profoundly hypothermic temperatures.
It is encouraging, however, that nondepolarizing, normokale-
mic AL in a physiologic, glucose-containing Krebs–Henseleit
solution spontaneously returns good functional recoveries in
the absence of an impermeant (eg, lactobionate, hydroxyethyl
starch, mannitol) or a pharmacopeia of additives. Finally, an-
other clinically relevant feature of AL cardioplegia, whether
cold or warm, that deserves consideration is the spontaneous
return of function without the need for defibrillation.17,24
Intermittent Flushes at Warmer Arrest
Temperatures (28C–30C)
In this study, we showed that 2-minute top-ups after every
18 minutes of AL cardioplegia at 28C to 30C yielded
spontaneous return of 80% of cardiac output after 2 hours
and 55% cardiac output after 6 hours (Tables 1 and 2). Fur-
ther, when AL cardioplegia was supplemented with 1-mmol/
L pyruvate, the return of cardiac output increased from 55%
to 75% after 60 minutes of reperfusion (P¼ .026); Table 2).
Possible reasons that the addition of 1-mmol/L pyruvate
improved aortic flow and cardiac output relative to 0- or
5-mmol/L pyruvate is difficult to reconcile without meta-The Journal of Thoracic and Cbolic analysis. It is known that pyruvate is a potent oxidizable
fuel for heart tissue, and has been shown to decrease the cy-
tosolic lactate/pyruvate ratio (lower the ratio of reduced to
oxidized nicotinamine adenoside), enhance the cytosolic ratio
of adenosine triphosphate to adenosine diphosphate and inor-
ganic phosphate, improve contractility, suppress hydroxyl
free-radical production, and reduce oxidative stress.25-27
In contrast, extracellular Celsior storage solution failed to
protect the heart after 6 hours at 28C to 30C (Table 1), with
no cardiac output during 60 minutes of reperfusion (Table 2,
Figure 1). Similarly, in 2004 we reported that St Thomas’
Hospital solution performed poorly under identical condi-
tions, with only 14% of hearts recovering function after 4
hours of arrest at 28 to 30C.17 Ou and colleagues28 further
reported that University of Wisconsin solution is not protec-
tive at warmer temperatures and may even be deleterious. To
be fair, Celsior (or, for that matter, University of Wisconsin
solution) was not designed for warmer arrest and storage
temperatures; it was originally designed as a perfusion fluid
during initial donor arrest, poststorage graft implantation,
and early reperfusion.20
Static Cold Storage, Intermittent Flushes, or
Continuous Perfusion?
Controversy abounds in the literature regarding the optimal
perfusion dynamics and ionic and metabolic composition for
arrest, storage, and reanimation of human donor hearts.1,2
Commonly used preservation solutions for cold static storage
are the University of Wisconsin, Celsior, Euro-Collins, and
Bretschneider solutions.8 Although intermittent flush tech-
niques similar to the method used in our study (or continuous
low-pressure infusion delivery during cold storage) are not
widely practiced today, their superiority has been experimen-
tally demonstrated during the past 20 years,11,29 as reviewed
by Nickless and associates23 and Jahania and colleagues.1
The major clinical objections to intermittent flush or continu-
ous perfusion methods appear to be based largely on logistics,
and not on efficacy, although myocardial extracellular edema
and associated decreased ventricular compliance have been
a concern with constant-infusion storage techniques.2,30
Some of these limitations have been partially solved by Hassa-
nein and coworkers31 and others who have developed portable
perfusion apparatus for use in donor human beating-heart pres-
ervation. The apparatus, which incorporates a low-pressure in-
fusion of a warm, oxygenated nutrient solution to the human
donor heart, is currently undergoing clinical trials in the United
Kingdom and Germany.
Possible Clinical Significance of the Normokalemic,
Nondepolarizing AL Paradigm for Heart Transplant
This study, which showed the versatility of cold and
warmer AL in a crystalloid composition, may be directly rel-
evant to all phases of heart transplant (donor harvest, stor-
age, and implantation). The particular focus of our workardiovascular Surgery c Volume 137, Number 1 205
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duce the negative impact of cold-to-warm wash and reperfu-
sion temperatures, during which major damage to the adult
or pediatric allograft often occurs.7,8,28 Currently, there is
no preservation solution that can preserve the functional hu-
man heart safely beyond 4 to 5 hours.
The versatility of AL infusion as the primary arrest and re-
animation strategy may be as follows: (1) AL induces rapid
electromechanical arrest (as seen in this study and in references
2, 17, and 24). (2) AL eliminates the need for high depolarizing
potassium, which can lead to unnatural transmembrane volt-
ages, ionic and metabolic imbalances, and electrical instability
in myocytes,14,15 endothelial cells and vascular smooth muscle
cells.12 High potassium is a potent vasoconstrictor and pro-
motes vasospasm of the coronary arteries in diseased hearts.11
(3) Adenosine has the ability (through A1 receptor activation)
to blunt the stimulatory effects of catecholamines,32 which
may help to protect the heart during the harvest period.33 (4)
AL maintains a lower CVR during prolonged storage (this
study and references 17 and 24). (5) AL has antiarrhythmic
properties that may be important to harvest, arrest, and reani-
mation34,35 and to sinus nodal protection. (6) AL has been
shown to preserve high-energy phosphates (adenosine triphos-
phate and phosphocreatine)during no- or low-flowischemia.36
(7) Both adenosine and lidocaine have potent anti-inflamma-
tory37 and anticoagulant properties,38 and may help to reduce
acute and chronic rejection. (8) AL arrest led to a spontaneous
return of improved left ventricular function against physio-
logic workloads after 6 hours of arrest, with recovery as great
as 75% of prearrest cardiac output (this study and reference
17). (9) AL versatility permits the incorporation of warmer har-
vest, preservation, and reanimation temperatures, which may
reduce the adverse effects of low perfusate temperatures on
myocardial ischemia tolerance, rheology, and endothelial dys-
function and may reduce the incidence of arrhythmias.11 (10)
Finally, AL solutions may help to rescue and stabilize the heart
and other organs during harvest from beating-heart and non–
beating heart donors.
We to thank Professor Jakob Vinten Johansen for his continued
scholarship and support for many years and throughout this study.
The adenosine–lidocaine composition has been trademarked
Adenocaine.
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